Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesFree Cash FlowNet Cash FlowShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Syndax Pharmaceuticals (SNDX) Other financing activities (2016 - 2022)

Historic Other financing activities for Syndax Pharmaceuticals (SNDX) over the last 8 years, with Q1 2022 value amounting to $92000.0.

  • Syndax Pharmaceuticals' Other financing activities rose 1645.57% to $92000.0 in Q1 2022 from the same period last year, while for Mar 2022 it was $13000.0, marking a year-over-year decrease of 1875.0%. This contributed to the annual value of $1000.0 for FY2020, which is 9945.05% down from last year.
  • Per Syndax Pharmaceuticals' latest filing, its Other financing activities stood at $92000.0 for Q1 2022, which was up 1645.57% from -$242000.0 recorded in Q4 2021.
  • Over the past 5 years, Syndax Pharmaceuticals' Other financing activities peaked at $207000.0 during Q4 2018, and registered a low of -$242000.0 during Q4 2020.
  • Its 5-year average for Other financing activities is $35941.2, with a median of $63000.0 in 2018.
  • In the last 5 years, Syndax Pharmaceuticals' Other financing activities soared by 350000.0% in 2018 and then tumbled by 52456.14% in 2020.
  • Over the past 5 years, Syndax Pharmaceuticals' Other financing activities (Quarter) stood at $207000.0 in 2018, then crashed by 72.46% to $57000.0 in 2019, then tumbled by 524.56% to -$242000.0 in 2020, then changed by 0.0% to -$242000.0 in 2021, then skyrocketed by 138.02% to $92000.0 in 2022.
  • Its Other financing activities was $92000.0 in Q1 2022, compared to -$242000.0 in Q4 2021 and $99000.0 in Q3 2021.